Skip to main content
PMC home page
OncoTargets and Therapy logoLink to OncoTargets and Therapy
. 2015 Nov 18;8:3361–3369. doi: 10.2147/OTT.S89275

Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic review

Jie Zhang 1,2,3,*, Shengfei Wang 1,2,3,*, Lei Wang 1,2,*, Rui Wang 1,2,*, Sufeng Chen 1,2, Bin Pan 1,2, Yihua Sun 1,2, Haiquan Chen 1,4,✉
PMCID: PMC4655977  PMID: 26604794

Abstract

Objective

B-cell-lymphoma-2 (Bcl-2) is a proto-oncogene that plays an important role in the regulation of apoptosis and cell survival. However, there are much conflicting data in the literature concerning the association between Bcl-2 and prognosis in non-small-cell lung cancer (NSCLC). There is little in the way of meta-analysis focused on Bcl-2 and its effect on NSCLC prognosis. This study was performed to provide an assessment of whether expression levels of Bcl-2 are associated with prognosis in patients with NSCLC.

Materials and methods

We searched PubMed, the Cochrane Library, and China National Knowledge Infrastructure for all eligible studies. The combined hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) in terms of overall survival were evaluated.

Results

Fifty published studies including 6,863 patients with lung cancer were included in this meta-analysis. Overall, Bcl-2 was expressed in 33% of the NSCLC tumors studied. Our analysis indicates that NSCLC patients with Bcl-2-positive expression have a better prognosis than those with Bcl-2-negative expression in both Asian and non-Asian study populations (HR 0.79, 95% CI 0.72–0.87, P<0.00001). However, Bcl-2-positive expression seems to have no significant impact on survival of stage I NSCLC patients.

Conclusion

Our results indicated that Bcl-2 might be a useful prognostic marker for NSCLC generally. Larger clinical trials are needed to confirm the prognostic value of Bcl-2 in stage I NSCLC.

Keywords: Bcl-2, non-small-cell lung cancer, meta-analysis, prognosis

Introduction

Lung cancer is the most common cause of cancer-related death worldwide. Non-small-cell lung cancer (NSCLC) accounts for >85% of primary lung cancers, and approximately two-thirds of NSCLC patients are diagnosed at an advanced stage.1 Pathological features, such as pathological stage, histological type, and lymph node metastasis, have been independent prognostic markers predicting the development of metastasis.2 However, they are imperfect, represent only crude measures of the biological behavior of a tumor, and cannot predict the optimal therapeutic course for the individual patient. Thus, it is important to identify biological markers which can predict survival.

The ability of cancer cells to avoid apoptosis and continue to proliferate is one of the fundamental hallmarks of cancer. B-cell-lymphoma-2 (Bcl-2) is a key regulator of the mitochondrial apoptotic pathway promoting survival by inhibition of adapters necessary for the activation and cleavage of caspases.3 The Bcl-2 gene was discovered in a follicular B-cell lymphoma, and its tumorigenic potential has been shown in animal models.4 Bcl-2 is overexpressed in a variety of human tumors including lung cancer.3,5

In lung cancer, the prognostic value of Bcl-2 expression has been analyzed by several groups, but results have been conflicting and controversial. One group investigated Bcl-2 expression in a meta-analysis of nine studies with a total of 673 small-cell lung cancer patients and concluded that Bcl-2 expression was associated with a better prognosis, but this did not reach significance.6 Also, although there are a large number of studies investigating the prognostic value of Bcl-2 expression in NSCLC survival, no consensus has been reached. These conflicting results have been reported from different laboratories. We, therefore, carried out a meta-analysis of data from published studies to quantitatively review the effect of Bcl-2 overexpression in tumor tissue on overall survival (OS) in patients with NSCLC.

Materials and methods

Search strategy and study selection

The search was performed by consulting the electronic database PubMed, the Cochrane Library, and China National Knowledge Infrastructure. Searches included the terms “non-small cell lung cancer” and “Bcl-2”. The keywords hit 553 citations. Manual selection of relevant studies was carried out based on the summary analysis. The citation lists of all retrieved articles were scanned to identify other potentially relevant reports.

The following criteria for eligibility among studies were set before collecting articles: 1) Bcl-2 expression was evaluated in primary NSCLC tissue. 2) Survival information at specific times was reported in the article. 3) Follow-up time exceeded 5 years. 4) Articles were published in English and in Chinese. 4) When several articles were published by the same authors or group, the newest or most informative single article was selected. Exclusion criteria were the following: 1) No information on survival was provided, or the hazard ratio (HR) of OS could not be calculated based on the given information. 2) Letters to editor, reviews, and articles published in a book or papers published in non-English. 3) Studies with radiotherapy or concurrent chemoradiotherapy treatment investigating response rates only.

Two authors (SW and JZ) did the search and identification independently, and selection of an article was reached by consensus. The following information was extracted from each report by the two authors independently: year of publication, patient size, time period of patient enrollment, patient source, histology, disease stage, test method, cutoff value, and survival data. If data from any of the above categories were not reported in the primary study, items were treated as “not applicable”.

Quality assessment

Quality assessment of each study was performed using the Newcastle–Ottawa Quality Assessment Scale for cohort studies. This scale is an 8-item instrument that allows for assessment of patient population and selection, study comparability, follow-up, and outcome of interest. The scale was recommended by the Cochrane Non-Randomized Studies Methods Working Group. Two investigators (JZ and SW) performed quality assessment independently. Disagreement was resolved by consensus.

Statistical analysis

Analysis of variance was used to compare the means of quality scores between different groups. For quantitative aggregation of survival results, HR and their 95% confidence intervals (CIs) were combined to give the effective value. The HR was calculated from the reported data directly by number of events. If data were presented in the form of Kaplan–Meier survival curve, we extracted them from the survival rates at specified times in order to reconstruct the HR estimate and its variance using methods reported by Parmar et al.7 Data were entered into the Cochrane Collaboration software, RevMan Version 5.0 for Windows (the Cochrane Collaboration, Oxford, UK). The Cochran’s test was used to assess the heterogeneity of included studies. For heterogeneity tests, P-value <0.05 was considered to indicate significance. If the test of heterogeneity was significant (P<0.05; I2>50%), the random-effect model was used. Otherwise, the fixed-effect model was used. By convention, an observed HR of <1 implied a better survival for the group with positive Bcl-2 expression. This impact of Bcl-2 on survival was considered as statistically significant if the 95% CI for the overall HR did not overlap.

Results

Studies selection and characteristics

Five hundred and fifty-three potentially relevant citations were reviewed (Figure 1). Among them, six studies were based on the same patient cohorts. Thus, the less informative ones were excluded (studies excluded were the following: Fontanini et al (1996), Laudanski et al (1995), and O’Byrne et al (2001); studies included were the following: Fontanini et al,53 Laudanski et al,35 and Cox et al37). Forty papers were review articles, 354 were not clinical studies including signal transduction, cell lines, animals, or pharmacogenomic studies, 13 were case reports, and the other 16 papers were designed without lung cancer. Ultimately, 50 studies3,8–56 that reported the prognostic value of Bcl-2 status for OS were analyzed. The total number of patients included was 6,863, ranging from 24 to 534 patients per study (median, 137). The major characteristics are shown in Table 1. These 50 studies included all lung cancer subtypes (n=46), adenocarcinomas only (n=2), or squamous cell carcinomas (SCCs) only (n=2). Twenty-nine studies had information for stages I–III, eight for advanced-stage (III–IV) disease, and 13 for all stages, I–IV. Forty-eight studies used immunohistochemistry to evaluate Bcl-2 expression, one used reverse transcription polymerase chain reaction, and one used Western blot.

Figure 1.

Figure 1

Open in a new tab

Flow chart of article selection in meta-analysis.

Note: Fifty studies involving 6,863 patients were analyzed.

Table 1.

Baseline characteristics of the 50 trials used in the meta-analysis

Studies Year Patients source Number of patients Method Stage Study quality points
Cakir et al8 2011 Turkey 166 IHC I–IV 6 out of 9
Anagnostou et al3 2010 USA/Greece 534 IHC I–IV 6 out of 9
Grimminger et al9 2010 Germany 91 RT-PCR I–IIIA 6 out of 9
Jeong et al10 2010 Republic of Korea 39 IHC IIIA–IIIB 5 out of 9
Porebska et al11 2009 Poland 30 IHC I–IV 6 out of 9
Lee et al12 2009 Republic of Korea 50 IHC IIIB–IV 7 out of 9
Renouf et al13 2009 Canada 451 IHC I–II 7 out of 9
Zhao et al14 2008 People’s Republic of China 62 IHC I–IIIA 6 out of 9
Yoo et al15 2007 Republic of Korea 219 IHC I–III 6 out of 9
Hu et al16 2006 People’s Republic of China 88 IHC I–III 6 out of 9
Wang et al17 2006 People’s Republic of China 111 IHC I–III 6 out of 9
Yaren et al18 2006 Turkey 69 IHC I–IV 6 out of 9
Yilmaz et al19 2005 Turkey 46 IHC I–IV 6 out of 9
Groeger et al20 2004 USA 76 IHC I–IV 5 out of 9
Shibata et al21 2004 Japan 120 IHC I–III 7 out of 9
Kren et al22 2004 USA 102 IHC I–IIIA 6 out of 9
Ludovini et al23 2004 Italy 85 IHC IIIA–IV 7 out of 9
Grossi et al24 2003 Italy 213 IHC I–IIIA 5 out of 9
Huang et al25 2003 USA 91 WB I–IV 6 out of 9
Gregorc et al26 2003 Italy 102 IHC IIIA–IV 7 out of 9
Han et al27 2003 Republic of Korea 34 IHC IIIB–IV 6 out of 9
Krug et al28 2003 USA 31 IHC IIIB–IV 8 out of 9
Poleri et al29 2003 Argentina 53 IHC I 8 out of 9
Tomita et al30 2003 Japan 60 IHC IIIA–IV 7 out of 9
Lai et al31 2002 Taiwan 114 IHC I–IIIA 6 out of 9
Hanaoka et al32 2002 Japan 70 IHC I–III 6 out of 9
Han et al33 2002 USA 85 IHC I 7 out of 9
Hwang et al34 2001 Republic of Korea 53 IHC I–IIIB 6 out of 9
Laudanski et al35 2001 Poland 102 IHC I–IIIA 6 out of 9
Tanaka et al36 2001 Japan 162 IHC I 8 out of 9
Cox et al37 2000 USA 178 IHC I–IIIA 6 out of 9
Moldvay et al38 2000 France 226 IHC I–IV 7 out of 9
van de Vaart et al39 2000 the Netherlands 24 IHC IIIA–IIIB 6 out of 9
Chen et al40 1999 Japan 40 IHC I 7 out of 9
D’Amico et al41 1999 USA 408 IHC I 8 out of 9
Huang et al42 1999 Japan 203 IHC I–IIIB 8 out of 9
Mehdi et al43 1999 USA 241 IHC I–II 6 out of 9
Silvestrini et al44 1998 Italy 101 IHC I–III 7 out of 9
Anton et al45 1997 USA 427 IHC I–IV 8 out of 9
Apolinario et al46 1997 the Netherlands 116 IHC I–IIIA 6 out of 9
Higashiyama et al47 1997 Japan 174 IHC I–IIIB 6 out of 9
Ishida et al48 1997 Japan 114 IHC I–IIIA 6 out of 9
Koukourakis et al49 1997 USA 107 IHC I–IIIA 6 out of 9
Pastorino et al50 1997 UK 485 IHC I 7 out of 9
O’Neill et al51 1996 Ireland 54 IHC I–IV 5 out of 9
Ohsaki et al52 1996 Japan 99 IHC I–IV 6 out of 9
Fontanini et al53 1995 Italy 89 IHC I–IIIA 5 out of 9
Ritter et al54 1995 USA 126 IHC I 7 out of 9
Walker et al55 1995 UK 27 IHC I–IV 6 out of 9
Pezzella et al56 1993 UK 115 IHC I–III 7 out of 9
Open in a new tab

Abbreviations: IHC, immunohistochemistry; RT-PCR, reverse transcription polymerase chain reaction; WB, Western blot.

In 50 studies evaluating Bcl-2 expression, the proportion of patients exhibiting Bcl-2 overexpression in individual studies ranged from 5% to 71%. Twenty-six out of the 50 studies identified Bcl-2 overexpression as an indicator of positive prognosis; Bcl-2 expression in six studies was significantly associated with poor prognosis. Eighteen studies showed no statistically significant impact of Bcl-2 overexpression on survival.

Quality assessment

We used the Newcastle–Ottawa Scale to perform quality assessment of all 50 studies. Studies that fulfill five or more of the eight criteria were higher quality studies. Overall, the total quality score of the included studies ranged from 5 to 8 (Table 1).

Impact of Bcl-2-positive expression on OS of NSCLC

The effect of Bcl-2 expression on OS was evaluated in 50 studies with a total of 6,863 patients. Overall, Bcl-2 was expressed in 33% of the NSCLCs studied. HRs were calculated from the reported data directly by number of events (25 out of 50), or data reading from Kaplan–Meier survival curve from the survival curves reading (25 out of 50). The combined HR was calculated using a random-effect model, and a value was obtained that was statistically significant (HR 0.79, 95% CI 0.72–0.87, P<0.00001), indicating that Bcl-2-positive expression was an indicator of better prognosis.

The data extracted were adequate to aggregate the studies of stage I NSCLC. When we aggregated the eight studies which reported data from 1,432 patients, no heterogeneity was found. The combined HR was not statistically significant (HR 0.93, 95% CI 0.80–1.07, P=0.50). Thus, no relationship between Bcl-2 and survival was observed for stage I NSCLC (Figure 2A).

Figure 2.

Figure 2

Figure 2

Open in a new tab

Meta-analysis (Forest plot) of 50 studies assessing Bcl-2 in NSCLC.

Notes: (A) Forest plot of stage I group analysis; pooled data from eight studies did not show significant impact on survival with Bcl-2-positive expression compared with those with Bcl-2-negative expression (HR 0.93, 95% CI 0.80–1.07, P=0.50). (B) Forest plot of stage I–III group analysis; pooled data from 29 studies showed that NSCLC patients with Bcl-2-positive expression have better prognosis than those with Bcl-2-negative expression (HR 0.77, 95% CI 0.69–0.89, P<0.0001). (C) Forest plot of stage III–IV group analysis; pooled data from eight studies showed that patients with Bcl-2-positive expression have better prognosis than those with Bcl-2-negative expression (HR 0.74, 95% CI 0.59–0.94, P=0.01). (D) Forest plot of all stage group analysis; pooled data from 13 studies did not show significant impact on survival in patients with Bcl-2-positive expression compared with those with Bcl-2-negative expression (HR 0.84, 95% CI 0.69–1.02, P=0.08). (E) Forest plot of SCC group analysis; pooled data from seven studies showed that patients with Bcl-2-positive expression have better prognosis than those with Bcl-2-negative expression (HR 0.54, 95% CI 0.32–0.90, P=0.02). (F) Forest plot of adenocarcinoma group analysis; pooled data from six studies did not show significant impact on survival in patients with Bcl-2-positive expression compared with those with Bcl-2-negative expression (HR 0.92, 95% CI 0.56–1.51, P=0.73).

Abbreviations: Bcl-2, B-cell-lymphoma-2; NSCLC, non-small-cell lung cancer; HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma.

When 29 studies containing 4,390 patients who had received radical surgery (I–III) were considered, highly significant heterogeneity was detected (χ2=92.48, P<0.00001; I2=70%). The random-effect model was used to perform meta-analysis, and the result was significant in favor of patients with positive Bcl-2 expression (HR 0.77, 95% CI 0.69–0.89, P<0.0001) (Figure 2B).

The advanced-stage subgroup included eight studies comprising 425 patients. Because no heterogeneity was found in this subgroup (χ2=7.77, P=0.35; I2=10%), the fixed-effect model was used to perform meta-analysis. The aggregated survival data also showed a good survival prognosis where there was Bcl-2-positive expression (HR 0.74, 95% CI 0.59–0.94, P=0.01) (Figure 2C).

Thirteen studies comprising 2,048 patients were included in the all-stage subgroup. The result of the test for heterogeneity was significant (χ2=52.56, P<0.0001; I2=77%), and then, the combined HR was calculated using a random-effect model. Bcl-2 expression was not significantly associated with OS (HR 0.84, 95% CI 0.69–1.02, P=0.08) (Figure 2D). There were not adequate data to aggregate studies of stage II or III disease.

The data extracted were also adequate to aggregate the studies of SCC and adenocarcinoma for subgroup analyses. When we aggregated seven studies that reported results for SCC, the combined HR was statistically significant (HR 0.54, 95% CI 0.32–0.90, P=0.02) (Figure 2E). We observed no statistically significant effect of Bcl-2 expression on survival in patients with adenocarcinoma, however (HR 0.92, 95% CI 0.56–1.51, P=0.73) (Figure 2F).

There were 32 studies from Europe and USA and 18 from East Asia. The combined HRs of East Asian studies and non-East Asian studies were 0.78 (95% CI 0.63–0.96, P<0.0001) and 0.82 (95% CI 0.72–0.92, P<0.0001), respectively. In both East Asian and European/USA populations, Bcl-2 expression was an indicator of better prognosis.

Discussion

Identification of prognostic factors allows the definition of high-risk groups of patients for whom further specific therapy might be necessary and stratification should thus be performed in randomized trials.

A previous meta-analysis showed an association between Bcl-2 positivity and better survival of patients with lung cancer.57 This analysis included 18 NSCLC, three neuroendocrine, and four small-cell lung cancer trials reported from 1993 to 1999. However, data were insufficient to evaluate the prognostic value of Bcl-2 in surgical cases. The effect of Bcl-2-positive expression on specific stage, such as stage I, advanced stages, and adenocarcinomas, was not assessed. We have improved upon that previous meta-analysis by including more recent studies and by generally using a more comprehensive search strategy.

In this meta-analysis, 50 published studies including 6,863 patients with lung cancer were included. Our analysis indicates that NSCLC patients with Bcl-2-positive expression have a better prognosis than those with Bcl-2-negative expression in both East Asian and non-East Asian study populations (HR 0.79, 95% CI 0.72–0.87, P<0.00001). However, Bcl-2 expression seems to have no significant impact on survival of stage I NSCLC patients.

The mechanisms through which Bcl-2 might exert its protective effect in NSCLC are unclear. One group demonstrated that Bcl-2 expression showed an association with biologic features, such as the absence of c-erb-B2 and mutant p53 expression, which define a better prognosis.58 Therefore, although bcl-2 is a proto-oncogene involved in oncogenesis, because of its ability to prolong cell survival through the inhibition of apoptosis, its expression may be associated with other features that define a more favorable prognosis. Bcl-2 may also suppress the proliferative activity of tumor cells. It has been reported that the proliferative activity of Bcl-2-positive tumors tended to be lower than that in negative tumors.51 Furthermore, the process of apoptosis involves many proteins such as antiapoptotic proteins (Bcl-2, Bcl-X) and proapoptotic proteins (Bax, Bak, Bad). Thus, it remains to be clarified if other proteins or bcl homologs potentiate the tumor suppressor role of Bcl-2 in NSCLC. Recently, Bcl-2 was found to inhibit DNA replication and DNA repair.59,60 Due to its dual function, NSCLC patients with Bcl-2-positive expression had a better prognosis than those with Bcl-2-negative expression in both Asian and non-Asian study populations in this analysis.

Some potentially important methodologic biases need to be discussed. When the analysis was limited to eight advanced-stage studies, or eight studies assessing Bcl-2 in stage I subgroup, heterogeneity was not detected. However, heterogeneity was detected when analyses were limited to the 18 East Asian studies or the seven studies including only SCC. Therefore, patient type and histologic type were not a major source of heterogeneity. The heterogeneity in this study could be explained by the stage or by differences in the method used to detect Bcl-2 status. Small sample size was also a source of bias. When the analysis was limited to >100 patients in studies in surgical group, no significant heterogeneity was detected (χ2=35.29, P=0.01; I2=46%).

Additional biases could be introduced by the methodology used. We performed a methodological assessment of the studies to avoid selection biases where possible. The comparison of the scores of the three groups (positive, nonsignificant, negative studies) showed no statistically significant difference, allowing a meaningful data aggregation.

In conclusion, Bcl-2-positive expression was associated with a better prognosis in patients with NSCLC, so Bcl-2 might be a useful prognostic marker.61 However, Bcl-2-positive expression seems to have no significant impact on survival of stage I patients as determined in our meta-analysis. These results should be confirmed by an adequately designed prospective study. Because there was only limited number of patients to test for Bcl-2 expression in platinum-based chemotherapy, these results need to be confirmed by well-designed prospective studies.

Acknowledgments

The authors acknowledge support from the National Natural Science Foundation of China (grant numbers 81101761 and 81172218), Shanghai science and technology commission foundation key project, Longhua Medicial Project (D25), Ministry of Education Returned Scientific Research Foundation, key project from the Shanghai Municipal Science and Technology Commission Foundation (14JC1401400), Trans-Century Training Programme Foundation for the Talents by the State Education Commission (to JZ), and key technology support project of the field of medicine and agriculture science from Shanghai Municipal Science and Technology Commission (15411951602).

Footnotes

Author contributions

JZ, LW, RW, and HC were involved in concept and design of the study. LW and JZ drafted the manuscript. All authors participated in acquisition, analysis, and interpretation of data, revised the manuscript, and read and approved the final version.

Disclosure

The authors declare that they have no conflicts of interest in this work.

References

  • 1.Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–229. doi: 10.3322/caac.20006. [DOI] [PubMed] [Google Scholar]
  • 2.Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260–271. doi: 10.1378/chest.08-0978. [DOI] [PubMed] [Google Scholar]
  • 3.Anagnostou VK, Lowery FJ, Zolota V, et al. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer. 2010;10:186. doi: 10.1186/1471-2407-10-186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Choi J, Choi K, Benveniste EN, et al. Bcl-2 promotes invasion and lung metastasis by inducing matrix metalloproteinase-2. Cancer Res. 2005;65:5554–5560. doi: 10.1158/0008-5472.CAN-04-4570. [DOI] [PubMed] [Google Scholar]
  • 5.Callagy GM, Webber MJ, Pharoah PD, Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer. 2008;8:153. doi: 10.1186/1471-2407-8-153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lawson MH, Cummings NM, Rassl DM, et al. Bcl-2 and beta1-integrin predict survival in a tissue microarray of small cell lung cancer. Br J Cancer. 2010;103:1710–1715. doi: 10.1038/sj.bjc.6605950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–2834. doi: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  • 8.Cakir E, Yilmaz A, Demirag F, et al. Prognostic significance of micropapillary pattern in lung adenocarcinoma and expression of apoptosis-related markers: caspase-3, bcl-2, and p53. APMIS. 2011;119:574–580. doi: 10.1111/j.1600-0463.2011.02778.x. [DOI] [PubMed] [Google Scholar]
  • 9.Grimminger PP, Schneider PM, Metzger R, et al. The prognostic role of Bcl-2 mRNA expression in curatively resected non-small cell lung cancer (NSCLC) Lung Cancer. 2010;70:82–87. doi: 10.1016/j.lungcan.2009.12.013. [DOI] [PubMed] [Google Scholar]
  • 10.Jeong SH, Jung JH, Han JH, et al. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy. Lung Cancer. 2010;68:288–294. doi: 10.1016/j.lungcan.2009.06.003. [DOI] [PubMed] [Google Scholar]
  • 11.Porebska I, Kosacka M, Wyrodek E, et al. Expression of p53, bcl-2 and nm 23 proteins in squamous cell lung cancer. Pneumonol Alergol Pol. 2009;77:131–137. Polish. [PubMed] [Google Scholar]
  • 12.Lee HW, Choi YW, Han JH, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer. 2009;65:377–382. doi: 10.1016/j.lungcan.2008.12.005. [DOI] [PubMed] [Google Scholar]
  • 13.Renouf DJ, Wood-Baker R, Ionescu DN, et al. BCL-2 expression is prognostic for improved survival in non-small cell lung cancer. J Thorac Oncol. 2009;4:486–491. doi: 10.1097/JTO.0b013e318199e03a. [DOI] [PubMed] [Google Scholar]
  • 14.Zhao ZH, Wang SF, Cong DG, Yu L, Wang J. Correlation of the expression of pokemon with p14 and bc1-2 and their effects on prognosis of non small cell lung cancer. Tumor. 2008;4:121–124. [Google Scholar]
  • 15.Yoo J, Jung JH, Lee MA, et al. Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. J Korean Med Sci. 2007;22:318–325. doi: 10.3346/jkms.2007.22.2.318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Hu X, Song N, Liu Y, et al. Prognostic value of Bcl-2 and cyclooxygenase expressions in non-small cell lung cancer. Chin J Cancer Prev Treat. 2006;4:1704–1708. [Google Scholar]
  • 17.Wang L, Sun L, Dong C, et al. Prognosis significance of expression of apoptosis, P53 and Bcl-2 in non-small cell lung cancer. Chin J Histochem Cytochem. 2006;4:156–162. [Google Scholar]
  • 18.Yaren A, Oztop I, Kargi A, et al. Bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis. Int J Clin Pract. 2006;60:675–682. doi: 10.1111/j.1368-5031.2006.00742.x. [DOI] [PubMed] [Google Scholar]
  • 19.Yilmaz A, Savaş I, Dizbay Sak S, et al. Distribution of Bcl-2 gene expression and its prognostic value in non-small cell lung cancer. Tuberk Toraks. 2005;53:323–329. [PubMed] [Google Scholar]
  • 20.Groeger AM, Esposito V, De Luca A, et al. Prognostic value of immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-small-cell lung cancers. Histopathology. 2004;44:54–63. doi: 10.1111/j.1365-2559.2004.01750.x. [DOI] [PubMed] [Google Scholar]
  • 21.Shibata Y, Hidaka S, Tagawa Y, Nagayasu T. Bcl-2 protein expression correlates with better prognosis in patients with advanced non-small cell lung cancer. Anticancer Res. 2004;24:1925–1928. [PubMed] [Google Scholar]
  • 22.Kren L, Brazdil J, Hermanova M, et al. Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol. 2004;12:44–49. doi: 10.1097/00129039-200403000-00009. [DOI] [PubMed] [Google Scholar]
  • 23.Ludovini V, Gregorc V, Pistola L, et al. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer. Lung Cancer. 2004;46:77–85. doi: 10.1016/j.lungcan.2004.03.018. [DOI] [PubMed] [Google Scholar]
  • 24.Grossi F, Loprevite M, Chiaramondia M, et al. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. Eur J Cancer. 2003;39:1242–1250. doi: 10.1016/s0959-8049(03)00232-6. [DOI] [PubMed] [Google Scholar]
  • 25.Huang CI, Neuberg D, Johnson BE, Wei JY, Christiani DC. Expression of bcl-2 protein is associated with shorter survival in nonsmall cell lung carcinoma. Cancer. 2003;98:135–143. doi: 10.1002/cncr.11461. [DOI] [PubMed] [Google Scholar]
  • 26.Gregorc V, Ludovini V, Pistola L, et al. Relevance of p53, bcl-2 and Rb expression on resistance to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer. 2003;39:41–48. doi: 10.1016/s0169-5002(02)00391-4. [DOI] [PubMed] [Google Scholar]
  • 27.Han JY, Hong EK, Choi BG, et al. Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. Med Oncol. 2003;20:355–362. doi: 10.1385/MO:20:4:355. [DOI] [PubMed] [Google Scholar]
  • 28.Krug LM, Miller VA, Filippa DA, Venkatraman E, Ng KK, Kris MG. Bcl-2 and bax expression in advanced non-small cell lung cancer: lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine. Lung Cancer. 2003;39:139–143. doi: 10.1016/s0169-5002(02)00443-9. [DOI] [PubMed] [Google Scholar]
  • 29.Poleri C, Morero JL, Nieva B, et al. Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis. Chest. 2003;123:1858–1867. doi: 10.1378/chest.123.6.1858. [DOI] [PubMed] [Google Scholar]
  • 30.Tomita M, Matsuzaki Y, Edagawa M, Shimizu T, Hara M, Onitsuka T. Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer. Eur J Surg Oncol. 2003;29:654–657. doi: 10.1016/s0748-7983(03)00138-0. [DOI] [PubMed] [Google Scholar]
  • 31.Lai RS, Wang JS, Hsu HK, Chang HC, Lin CH, Lin MH. Prognostic evaluation of the expression of p53 and bcl-2 oncoproteins in patients with surgically resected non-small cell lung cancer. Jpn J Clin Oncol. 2002;32:393–397. doi: 10.1093/jjco/hyf084. [DOI] [PubMed] [Google Scholar]
  • 32.Hanaoka T, Nakayama J, Haniuda M, Sato TA. Immunohistochemical demonstration of apoptosis-regulated proteins, Bcl-2 and Bax, in resected non-small-cell lung cancers. Int J Clin Oncol. 2002;7:152–158. doi: 10.1007/s101470200022. [DOI] [PubMed] [Google Scholar]
  • 33.Han H, Landreneau RJ, Santucci TS, et al. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum Pathol. 2002;33:105–110. doi: 10.1053/hupa.2002.30183. [DOI] [PubMed] [Google Scholar]
  • 34.Hwang JH, Lim SC, Kim YC, Park KO, Ahn SJ, Chung WK. Apoptosis and bcl-2 expression as predictors of survival in radiation-treated non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2001;50:13–18. doi: 10.1016/s0360-3016(00)01558-3. [DOI] [PubMed] [Google Scholar]
  • 35.Laudanski J, Niklinska W, Burzykowski T, Chyczewski L, Niklinski J. Prognostic significance of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer. Eur Respir J. 2001;17:660–666. doi: 10.1183/09031936.01.17406600. [DOI] [PubMed] [Google Scholar]
  • 36.Tanaka F, Otake Y, Yanagihara K, et al. Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer. Br J Cancer. 2001;84:263–269. doi: 10.1054/bjoc.2000.1579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Cox G, Walker RA, Muller S, Abrams KR, Steward WP, O’Byrne KJ. Does immunointensity account for the differences in prognostic significance of Bcl-2 expression in non-small cell lung cancer? Pathol Oncol Res. 2000;6:87–92. doi: 10.1007/BF03032355. [DOI] [PubMed] [Google Scholar]
  • 38.Moldvay J, Scheid P, Wild P, et al. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res. 2000;6:1125–1134. [PubMed] [Google Scholar]
  • 39.van de Vaart PJ, Belderbos J, de Jong D, et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer. 2000;89:160–166. [PubMed] [Google Scholar]
  • 40.Chen Y, Sato M, Fujimura S, et al. Expression of Bcl-2, Bax, and p53 proteins in carcinogenesis of squamous cell lung cancer. Anticancer Res. 1999;19:1351–1356. [PubMed] [Google Scholar]
  • 41.D’Amico TA, Massey M, Herndon JE, 2nd, Moore MB, Harpole DH., Jr A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg. 1999;117:736–743. doi: 10.1016/s0022-5223(99)70294-1. [DOI] [PubMed] [Google Scholar]
  • 42.Huang C, Kohno N, Inufusa H, Kodama K, Taki T, Miyake M. Over-expression of bax associated with mutations in the loop-sheet-helix motif of p53. Am J Pathol. 1999;155:955–965. doi: 10.1016/s0002-9440(10)65195-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Mehdi SA, Tatum AH, Newman NB, et al. Prognostic markers in resected stage I and II non small-cell lung cancer: an analysis of 260 patients with 5 year follow-up. Clin Lung Cancer. 1999;1:59–67. doi: 10.3816/clc.1999.n.004. discussion 68–59. [DOI] [PubMed] [Google Scholar]
  • 44.Silvestrini R, Costa A, Lequaglie C, et al. Bcl-2 protein and prognosis in patients with potentially curable non-small-cell lung cancer. Virchows Arch. 1998;432:441–444. doi: 10.1007/s004280050188. [DOI] [PubMed] [Google Scholar]
  • 45.Anton RC, Brown RW, Younes M, Gondo MM, Stephenson MA, Cagle PT. Absence of prognostic significance of bcl-2 immunopositivity in non-small cell lung cancer: analysis of 427 cases. Hum Pathol. 1997;28:1079–1082. doi: 10.1016/s0046-8177(97)90062-9. [DOI] [PubMed] [Google Scholar]
  • 46.Apolinario RM, van der Valk P, de Jong JS, et al. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol. 1997;15:2456–2466. doi: 10.1200/JCO.1997.15.6.2456. [DOI] [PubMed] [Google Scholar]
  • 47.Higashiyama M, Doi O, Kodama K, Yokouchi H, Nakamori S, Tateishi R. bcl-2 oncoprotein in surgically resected non-small cell lung cancer: possibly favorable prognostic factor in association with low incidence of distant metastasis. J Surg Oncol. 1997;64:48–54. doi: 10.1002/(sici)1096-9098(199701)64:1<48::aid-jso10>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  • 48.Ishida H, Irie K, Itoh T, Furukawa T, Tokunaga O. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer. 1997;80:1034–1045. [PubMed] [Google Scholar]
  • 49.Koukourakis MI, Giatromanolaki A, O’Byrne KJ, et al. Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. Int J Cancer. 1997;74:65–570. doi: 10.1002/(sici)1097-0215(19971219)74:6<565::aid-ijc1>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  • 50.Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol. 1997;15:2858–2865. doi: 10.1200/JCO.1997.15.8.2858. [DOI] [PubMed] [Google Scholar]
  • 51.O’Neill AJ, Staunton MJ, Gaffney EF. Apoptosis occurs independently of bcl-2 and p53 over-expression in non-small cell lung carcinoma. Histopathology. 1996;29:45–50. doi: 10.1046/j.1365-2559.1996.d01-478.x. [DOI] [PubMed] [Google Scholar]
  • 52.Ohsaki Y, Toyoshima E, Fujiuchi S, et al. bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time. Clin Cancer Res. 1996;2:915–920. [PubMed] [Google Scholar]
  • 53.Fontanini G, Vignati S, Bigini D, et al. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer. 1995;71:1003–1007. doi: 10.1038/bjc.1995.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Ritter JH, Dresler CM, Wick MR. Expression of bcl-2 protein in stage T1N0M0 non-small cell lung carcinoma. Hum Pathol. 1995;4:1227–1232. doi: 10.1016/0046-8177(95)90198-1. [DOI] [PubMed] [Google Scholar]
  • 55.Walker C, Robertson L, Myskow M, Dixon G. Expression of the BCL-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas. Br J Cancer. 1995;72:164–169. doi: 10.1038/bjc.1995.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Pezzella F, Turley H, Kuzu I, et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med. 1993;329:690–694. doi: 10.1056/NEJM199309023291003. [DOI] [PubMed] [Google Scholar]
  • 57.Martin B, Paesmans M, Berghmans T, et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2003;89:55–64. doi: 10.1038/sj.bjc.6601095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Martinez-Arribas F, Alvarez T, Del Val G, et al. Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level. Anticancer Res. 2007;27:219–222. [PubMed] [Google Scholar]
  • 59.Maohua X, Yun Y, Taofeek KO, et al. Bcl-2 induces DNA replication stress by inhibiting rib nucleotide reductase. Cancer Res. 2014;74(1):212–223. doi: 10.1158/0008-5472.CAN-13-1536-T. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Maohua X, Dongkyoo P, Shuo Y, et al. Bcl-2 inhibits recruitment of Mre11 complex to DNA double-strand breaks in response to high-linear energy transfer radiation. Nucleic Acids Res. 2015;43(2):960–972. doi: 10.1093/nar/gku1358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Schmidt LH, Görlich D, Spieker T, et al. Prognostic impact of Bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non-small-cell lung cancer. J Thorac Oncol. 2014;9(9):1294–1304. doi: 10.1097/JTO.0000000000000243. [DOI] [PubMed] [Google Scholar]

Articles from OncoTargets and therapy are provided here courtesy of Dove Press

RESOURCES